Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.
Publication/Presentation Date
1-1-2016
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors have proven to be successful agents in inducing synthetic lethality in several malignancies. Several PARP inhibitors have reached clinical trial testing for treatment in different cancers, and, recently, Olaparib (AZD2281) has gained both United States Food and Drug Administration (USFDA) and the European Commission (EC) approval for use in BRCA-mutated advanced ovarian cancer treatment. The need to identify biomarkers, their interactions in DNA damage repair pathways, and their potential utility in identifying patients who are candidates for PARP inhibitor treatment is well recognized. In this review, we detail many of the biomarkers that have been investigated for their ability to predict both PARP inhibitor sensitivity and resistance in preclinical studies as well as the results of several clinical trials that have tested the safety and efficacy of different PARP inhibitor agents in BRCA and non-BRCA-mutated cancers.
Volume
2016
First Page
2346585
Last Page
2346585
ISSN
2314-6141
Published In/Presented At
Murata, S., Zhang, C., Finch, N., Zhang, K., Campo, L., & Breuer, E. K. (2016). Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine. BioMed research international, 2016, 2346585. https://doi.org/10.1155/2016/2346585
Disciplines
Medicine and Health Sciences
PubMedID
27642590
Department(s)
Fellows and Residents
Document Type
Article